Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertension: HELP
Articles by Massimo Volpe
Based on 128 articles published since 2008
||||

Between 2008 and 2019, Massimo Volpe wrote the following 128 articles about Hypertension.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
1 Guideline Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. 2017

Volpe, Massimo / Tocci, Giuliano / de la Sierra, Alejandro / Kreutz, Reinhold / Laurent, Stéphane / Manolis, Athanasios J / Tsioufis, Kostantinos. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-39, 00189, Rome, Italy. massimo.volpe@uniroma1.it. · IRCCS Neuromed, Via Atinense, 18, 86077, Pozzilli, Isernia, Italy. massimo.volpe@uniroma1.it. · Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-39, 00189, Rome, Italy. · IRCCS Neuromed, Via Atinense, 18, 86077, Pozzilli, Isernia, Italy. · Department of Internal Medicine, Hospital Mútua Terrassa, University of Barcelona, Plaça del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain. · Department of Clinical Pharmacology and Toxicology, Charité, Universitätsmedizin Berlin, 10117, Berlin, Germany. · Corporate Member of Freie Universität Berlin, Berlin, Germany. · Humboldt-Universität zu Berlin, Berlin, Germany. · Berlin Institute of Health, Berlin, Germany. · Department of Pharmacology and INSERM U 970, European Georges Pompidou Hospital, Université Paris-Descartes and Assistance Publique Hôpitaux de Paris, 56 rue Leblanc, 75015, Paris, France. · Department of Cardiology, Asclepeion General Hospital, Athens, Greece. · Hippokration Hospital, National and Kapodistrian University of Athens, Vas Sofias 114, 11527, Athens, Greece. ·High Blood Press Cardiovasc Prev · Pubmed #29086364.

ABSTRACT: Despite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (< 140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbidities contribute to the disparity between the potential and actual BP control rate. Previously we published a practical therapeutic platform for the treatment of hypertension based on clinical evidence, guidelines, best practice and clinical experience. This platform provides a personalised treatment approach and can be used to improve BP control and simplify treatment. It uses long-acting, effective and well-tolerated angiotensin receptor blocker (ARB) olmesartan, in combination with a calcium channel blocker amlodipine, and/or a thiazide diuretic hydrochlorothiazide. These drugs were selected based on the availability in most European Countries of single-pill, fixed formulations in a wide range of doses for both dual- and triple-drug combinations. The platform approach could be applied to other ARBs or angiotensin-converting enzyme inhibitors available in single-pill, fixed-dose combinations. Here, we present an update, which takes into account the results of the recently published studies and extends the applicability of the platform to common conditions that are often neglected or poorly considered in clinical practice guidelines.

2 Guideline Clinical management of resistant hypertension: practical recommendations from the Italian Society of Hypertension (SIIA). 2013

Veglio, Franco / Grassi, Guido / Mancia, Giuseppe / Volpe, Massimo / Anonymous300767. ·Chair of Internal Medicine and Hypertension Center, Department of Medical Sciences, School of Medicine, University of Turin, Turin, Italy, centroiperten.torino@libero.it. ·High Blood Press Cardiovasc Prev · Pubmed #23949949.

ABSTRACT: According to recent hypertension guidelines, resistant hypertension is a clinical condition characterized by the presence of BP values above the recommended limits of the reference values (BP >140/90 mmHg). The prevalence of this clinical condition is about 10 % of the essential hypertensives. A proper diagnosis and management of resistant hypertension should go trough careful, mandatory clinical step, aimed at excluding the presence of pseudo-resistance hypertension. In this report, we summarized the practical recommendations are targeting both the general practitioner and the specialist who play an active role in the clinical management of patients with arterial hypertension.

3 Guideline Clinical management of coronary heart disease in hypertension : practical recommendations from the Italian Society of Hypertension (SIIA). 2013

Volpe, Massimo / Trimarco, Bruno / Battistoni, Allegra / Mancia, Giuseppe / Anonymous5460766. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome "Sapienza", Sant'Andrea Hospital, Via di Grottarossa 1035-39, 00189, Rome, Italy, massimo.volpe@uniroma1.it. ·High Blood Press Cardiovasc Prev · Pubmed #23943342.

ABSTRACT: -- No abstract --

4 Guideline 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013

Mancia, Giuseppe / Fagard, Robert / Narkiewicz, Krzysztof / Redon, Josep / Zanchetti, Alberto / Böhm, Michael / Christiaens, Thierry / Cifkova, Renata / De Backer, Guy / Dominiczak, Anna / Galderisi, Maurizio / Grobbee, Diederick E / Jaarsma, Tiny / Kirchhof, Paulus / Kjeldsen, Sverre E / Laurent, Stéphane / Manolis, Athanasios J / Nilsson, Peter M / Ruilope, Luis Miguel / Schmieder, Roland E / Sirnes, Per Anton / Sleight, Peter / Viigimaa, Margus / Waeber, Bernard / Zannad, Faiez / Redon, Josep / Dominiczak, Anna / Narkiewicz, Krzysztof / Nilsson, Peter M / Burnier, Michel / Viigimaa, Margus / Ambrosioni, Ettore / Caufield, Mark / Coca, Antonio / Olsen, Michael Hecht / Schmieder, Roland E / Tsioufis, Costas / van de Borne, Philippe / Zamorano, Jose Luis / Achenbach, Stephan / Baumgartner, Helmut / Bax, Jeroen J / Bueno, Héctor / Dean, Veronica / Deaton, Christi / Erol, Cetin / Fagard, Robert / Ferrari, Roberto / Hasdai, David / Hoes, Arno W / Kirchhof, Paulus / Knuuti, Juhani / Kolh, Philippe / Lancellotti, Patrizio / Linhart, Ales / Nihoyannopoulos, Petros / Piepoli, Massimo F / Ponikowski, Piotr / Sirnes, Per Anton / Tamargo, Juan Luis / Tendera, Michal / Torbicki, Adam / Wijns, William / Windecker, Stephan / Clement, Denis L / Coca, Antonio / Gillebert, Thierry C / Tendera, Michal / Rosei, Enrico Agabiti / Ambrosioni, Ettore / Anker, Stefan D / Bauersachs, Johann / Hitij, Jana Brguljan / Caulfield, Mark / De Buyzere, Marc / De Geest, Sabina / Derumeaux, Geneviève Anne / Erdine, Serap / Farsang, Csaba / Funck-Brentano, Christian / Gerc, Vjekoslav / Germano, Giuseppe / Gielen, Stephan / Haller, Herman / Hoes, Arno W / Jordan, Jens / Kahan, Thomas / Komajda, Michel / Lovic, Dragan / Mahrholdt, Heiko / Olsen, Michael Hecht / Ostergren, Jan / Parati, Gianfranco / Perk, Joep / Polonia, Jorge / Popescu, Bogdan A / Reiner, Zeljko / Rydén, Lars / Sirenko, Yuriy / Stanton, Alice / Struijker-Boudier, Harry / Tsioufis, Costas / van de Borne, Philippe / Vlachopoulos, Charalambos / Volpe, Massimo / Wood, David A. ·Centro di Fisiologia Clinica e Ipertensione, Università Milano-Bicocca, Milano, Italy. giuseppe.mancia@unimib.it ·Eur Heart J · Pubmed #23771844.

ABSTRACT: -- No abstract --

5 Guideline 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. 2013

Volpe, Massimo / Rosei, Enrico Agabiti / Ambrosioni, Ettore / Cottone, Santina / Cuspidi, Cesare / Borghi, Claudio / De Luca, Nicola / Fallo, Francesco / Ferri, Claudio / Morganti, Alberto / Muiesan, Maria Lorenza / Sarzani, Riccardo / Sechi, Leonardo / Virdis, Agostino / Tocci, Giuliano / Trimarco, Bruno / Filippi, Alessandro / Mancia, Giuseppe / Anonymous1470754. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-39, 00189, Rome, Italy. massimo.volpe@uniroma1.it ·High Blood Press Cardiovasc Prev · Pubmed #23536324.

ABSTRACT: Observational clinical studies have demonstrated that only 30-40% of patients with arterial hypertension achieve the recommended blood pressure goals (below 140/90 mmHg). In contrast, interventional trials consistently showed that it is possible to achieve effective blood pressure targets in about 70% of treated hypertensive patients with different cardiovascular risk profiles, especially through the use of rational, effective and well tolerated combination therapies. In order to bridge the gap between current and desired blood pressure control and to achieve more effective prevention of cardiovascular diseases, the Italian Society of Hypertension (SIIA) has developed an interventional strategy aimed at reaching nearly 70% of treated controlled hypertensive patients by 2015. This ambitious goal can be realistically achieved by a more rational use of modern tools and supports, and also through the use of combination therapy in hypertension in daily clinical practice, especially if this approach can be simplified into a single pill (fixed combination therapy), which is a therapeutic option now also available in Italy. Since about 70-80% of treated hypertensive patients require a combination therapy based on at least two classes of drugs in order to achieve the recommended blood pressure goals, it is of key importance to implement this strategy in routine clinical practice. Amongst the various combination therapies currently available for hypertension treatment and control, the use of those strategies based on drugs that antagonize the renin-angiotensin system, such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) and ACE inhibitors, in combination with diuretics and/or calcium channel blockers, has been shown to significantly reduce the risk of major cardiovascular events and to improve patient compliance to treatment, resulting in a greater antihypertensive efficacy and better tolerability compared with monotherapy. The present document of the Italian Society of Arterial Hypertension (SIIA) aims to gather the main indications for the implementation of combination therapy in the treatment of hypertension, in order to improve blood pressure control in Italy.

6 Guideline Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure. 2012

Volpe, Massimo / Rosei, Enrico Agabiti / Ambrosioni, Ettore / Cottone, Santina / Cuspidi, Cesare / Borghi, Claudio / De Luca, Nicola / Fallo, Francesco / Ferri, Claudio / Mancia, Giuseppe / Morganti, Alberto / Muiesan, Maria Lorenza / Sarzani, Riccardo / Sechi, Leonardo / Tocci, Giuliano / Virdis, Agostino / Anonymous5210750. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome "Sapienza", Sant' Andrea Hospital, and IRCCS Neuromed, Rome, Via di Grottarossa 1035-39, 00189, Pozzilli, Isernia, Rome, Italy. massimo.volpe@uniroma1.it ·High Blood Press Cardiovasc Prev · Pubmed #23430669.

ABSTRACT: Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below 140/90 mmHg or below 130/80 mmHg in patients with type 2 diabetes mellitus or nephropathy) are not achieved in the presence of a therapeutic strategy that includes lifestyle changes and at least three classes of antihypertensive drugs, including a diuretic, at adequate doses. Recently, an innovative non-pharmacological option has become available for treating resistant hypertension. Sympathetic denervation of renal arteries is a minimally invasive procedure that is performed via percutaneous access from the femoral artery. It consists of radiofrequency ablation of the afferent and efferent nerves of the renal sympathetic nervous system, with consequent isolation of renal parenchymal and juxtaglomerular structures from abnormal stimulation of the efferent adrenergic system. The present position paper of the Italian Society of Hypertension (SIIA) offers a diagnostic and therapeutic approach for the proper identification and effective clinical management of patients with resistant hypertension, who are candidates for renal artery denervation. These indications may have important implications not only from a clinical point of view, but also from an economic point of view, since a proper identification of patients with true resistant hypertension and an accurate selection of patients suitable for the procedure of renal denervation can contribute to an improved control of blood pressure, and thus a reduced risk of cardiovascular and cerebrovascular complications in these patients.

7 Guideline [Strategies for improving blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. 2012 Position paper of the Italian Society of Hypertension]. 2012

Volpe, Massimo / Ambrosioni, Ettore / Borghi, Claudio / Cottone, Santina / Cuspidi, Cesare / De Luca, Nicola / Fallo, Francesco / Ferri, Claudio / Morganti, Alberto / Muiesan, Maria Lorenza / Sarzani, Riccardo / Sechi, Leonardo / Virdis, Agostino / Tocci, Giuliano / Agabiti-Rosei, Enrico / Trimarco, Bruno / Filippi, Alessandro / Mancia, Giuseppe / Anonymous4680743. ·Cattedra e Struttura Complessa di Cardiologia, Dipartimento di Medicina Clinica e Molecolare, Sapienza Universitá di Roma, Azienda Ospedaliera Sant'Andrea, Roma. massimo.volpe@uniroma1.it ·G Ital Cardiol (Rome) · Pubmed #23196689.

ABSTRACT: Observational studies demonstrate that the proportion of treated hypertensive patients who attain the recommended blood pressure goals (140/90 mmHg) does not exceed 30-40%. Conversely, clinical trials have consistently shown that effective blood pressure control within the recommended targets can be achieved in 70-80% of treated hypertensive patients with different cardiovascular risk profile, especially when appropriate, effective and well tolerated combination therapies are used. In order to bridge the gap between current and optimal blood pressure control rates and to achieve a more effective cardiovascular prevention, the Italian Society of Hypertension has recently developed an interventional strategy that aims to approximate 70% of treated controlled patients by 2015. This ambitious goal can be realistically achieved by the appropriate use of modern aids and tools, also including the implementation of combination therapy, especially if this approach can be simplified into a single pill, now available in Italy. At present, 70-80% of hypertensive patients require combination therapies based on at least two classes of antihypertensive drugs to achieve the recommended blood pressure goals. It is therefore of paramount importance to implement this strategy in routine clinical practice. Among the different combination therapies, the use of combination strategies based on drugs inhibiting the renin-angiotensin system, such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors, combined with diuretics and/or calcium-channel blockers, have demonstrated to significantly reduce the rates of major cardiovascular events and discontinuations from prescribed therapies, resulting in higher antihypertensive efficacy and better tolerability than monotherapy. The present document of the Italian Society of Hypertension aims to provide main indications for implementing combination therapy in the clinical management of hypertension in order to improve blood pressure control in Italy.

8 Guideline [Renal denervation for the treatment of resistant hypertension: definition, patient selection and description of the procedure. 2012 Position paper of the Italian Society of Hypertension]. 2012

Volpe, Massimo / Agabiti-Rosei, Enrico / Ambrosioni, Ettore / Cottone, Santina / Cuspidi, Cesare / Borghi, Claudio / De Luca, Nicola / Fallo, Francesco / Ferri, Claudio / Mancia, Giuseppe / Morganti, Alberto / Muiesan, Maria Lorenza / Sarzani, Riccardo / Sechi, Leonardo / Tocci, Giuliano / Virdis, Agostino / Anonymous4670743. ·Cattedra e Struttura Complessa di Cardiologia, Dipartimento di Medicina Clinica e Molecolare, Sapienza Universitá di Roma, Azienda Ospedaliera Sant'Andrea, Roma. massimo.volpe@uniroma1.it ·G Ital Cardiol (Rome) · Pubmed #23196688.

ABSTRACT: Hypertension is responsible for a relevant burden of cardiovascular morbidity and mortality worldwide. Although several appropriate and integrated pharmacological strategies are available, blood pressure control still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on overall cardiovascular risk, since it significantly increases the risk of both macrovascular and microvascular complications. Hypertension is arbitrarily defined as "resistant" or "refractory" when recommended blood pressure goals (clinic blood pressure <140/90 mmHg, or <130/80 mmHg in patients with type 2 diabetes mellitus) are not achieved, despite changes in lifestyle and treatment with adequate doses of at least three antihypertensive drugs from different classes, including a diuretic. A new non-pharmacological option for the treatment of patients with resistant hypertension has recently become available. Renal sympathetic denervation is a minimally invasive procedure performed via femoral access that uses radiofrequency catheter ablation to disable renal sympathetic afferent and efferent nerves. It results in isolation of renal parenchymal and juxtaglomerular cells from the abnormal enhancement of renal adrenergic nerve activity. The present position paper of the Italian Society of Hypertension provides a diagnostic and therapeutic approach to the early identification and effective clinical management of patients with resistant hypertension, who may be candidates for renal denervation. These indications may have important implications not only from a clinical viewpoint but also from an economic perspective. The accurate identification of patients with resistant hypertension and the appropriate selection of patients eligible for this procedure may help improve blood pressure control and reduce the risk of cardiovascular and cerebrovascular complications in these patients.

9 Guideline [Hypertensive heart disease: diagnostic and therapeutic guidelines]. 2008

Rosei, Enrico Agabiti / de Simone, Giovanni / Mureddu, Gian Francesco / Trimarco, Bruno / Verdecchia, Paolo / Volpe, Massimo / Muiesan, Maria Lorenza / Ambrosioni, Ettore / Bernini, Giampaolo / Cerasola, Giovanni / de Divitiis, Oreste / Di Somma, Salvatore / Esposti, Ezio Degli / Fiorentini, Cesare / Ganau, Antonello / Grandi, Anna Maria / Grassi, Guido / Leonetti, Gastone / Mancia, Giuseppe / Manfellotto, Dario / Mezzetti, Andrea / Palombo, Carlo / Perlini, Stefano / Pessina, Achille / Rappelli, Alessandro / Rossi, Gianpaolo / Salvetti, Antonio / Veglio, Franco / Anonymous1390605 / Anonymous1400605 / Anonymous1410605. ·Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi, c/o II Medicina Generale, Spedali Civili, Piazzale Spedali Civili, 1 25123 Brescia. ·G Ital Cardiol (Rome) · Pubmed #18681395.

ABSTRACT: -- No abstract --

10 Editorial Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. 2019

Volpe, Massimo / Gallo, Giovanna / Battistoni, Allegra / Tocci, Giuliano. ·Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy. massimo.volpe@uniroma1.it. · IRCCS Neuromed, Pozzilli (IS), Italy. massimo.volpe@uniroma1.it. · Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy. · IRCCS Neuromed, Pozzilli (IS), Italy. ·High Blood Press Cardiovasc Prev · Pubmed #30604199.

ABSTRACT: This is a review article aiming to make focus on the changes made in the most recent sets of clinical recommendations and indications from European Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines for the management of arterial hypertension. In particular, in this article we attempted to focus on the main new elements introduced in order to meet the need of doctors to adhere to guidelines and to provide their patients with the most updated recommendations for the clinical management of hypertension.

11 Editorial The "hidden side of the moon" in hypertension: When and why is dangerous low diastolic blood pressure? 2019

Volpe, Massimo / Battistoni, Allegra / Gallo, Giovanna / Carnevale, Daniela. ·Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy. Electronic address: massimo.volpe@uniroma1.it. · Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. · IRCCS Neuromed, Pozzilli, Italy; Department of Molecular Medicine, Sapienza University of Rome, Italy. ·Int J Cardiol · Pubmed #30360994.

ABSTRACT: -- No abstract --

12 Editorial Search of multiple markers of organ damage for better cardiovascular risk stratification in hypertension: Role of "SHATS" syndrome in the clinical practice. 2018

Tocci, Giuliano / Presta, Vivianne / Figliuzzi, Ilaria / Volpe, Massimo. ·Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy. Electronic address: giuliano.tocci@uniroma1.it. · Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. · Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy. ·Int J Cardiol · Pubmed #29754912.

ABSTRACT: -- No abstract --

13 Editorial Hypertension Across the Atlantic: A Sprint or a Marathon? 2017

Volpe, Massimo / Citoni, Barbara / Coluccia, Roberta / Battistoni, Allegra / Tocci, Giuliano. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. massimo.volpe@uniroma1.it. · IRCCS Neuromed, Pozzilli, IS, Italy. massimo.volpe@uniroma1.it. · Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. · IRCCS Neuromed, Pozzilli, IS, Italy. ·High Blood Press Cardiovasc Prev · Pubmed #28451910.

ABSTRACT: -- No abstract --

14 Editorial Angiotensin II-Linked Hypothesis to Understand the Advantage of the Coevolution of Hypertension and Malaria: "Sympathy for the Devil". 2016

Volpe, Massimo / Battistoni, Allegra / Mancia, Giuseppe. ·From the Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Italy (M.V., A.B.) · IRCCS Neuromed, Pozzilli, Italy (M.V.) · and University of Milano-Bicocca and the Istituto Clinico Universitario Policlinico di Monza,Verano Brianza Milan, Italy (G.M.). ·Circ Res · Pubmed #27789579.

ABSTRACT: -- No abstract --

15 Editorial New Opportunities for Monitoring Blood Pressure Control and Awareness in the Population: Insights from 12-Year Editions of the World Hypertension Day. 2016

Volpe, Massimo / Tocci, Giuliano / Borghi, Claudio / Parati, Gianfranco. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-9, 00189, Rome, Italy. massimo.volpe@uniroma1.it. · IRCCS Neuromed, Pozzilli, Italy. massimo.volpe@uniroma1.it. · Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-9, 00189, Rome, Italy. · IRCCS Neuromed, Pozzilli, Italy. · Internal Medicine, University of Bologna, Bologna, Italy. · Department of Clinical Medicine and Prevention, Centro Ricerche Cliniche, Istituto Auxologico Italiano IRCCS, University of Milano Bicocca, Milan, Italy. ·High Blood Press Cardiovasc Prev · Pubmed #27744587.

ABSTRACT: -- No abstract --

16 Editorial Managing hypertension after acute coronary syndrome: missing clinical evidence promote retrospective clues. 2015

Volpe, Massimo / Tocci, Giuliano. ·aDivision of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome 'Sapienza', Sant'Andrea Hospital, Rome bIRCCS Neuromed, Pozzilli, Italy. ·J Hypertens · Pubmed #25915873.

ABSTRACT: -- No abstract --

17 Editorial Impact of the direct angiotensin II type 2 receptor stimulation on renal function toward a sex-specific therapeutic approach for hypertension. 2014

Savoia, Carmine / Volpe, Massimo. · ·Hypertension · Pubmed #24842919.

ABSTRACT: -- No abstract --

18 Editorial Reducing therapeutic inertia to improve blood pressure control: the Spanish lesson. 2014

Volpe, Massimo / Tocci, Giuliano. ·aDivision of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome 'Sapienza', Sant'Andrea Hospital, Rome bIRCCS Neuromed, Pozzilli, Italy. ·J Hypertens · Pubmed #24695393.

ABSTRACT: -- No abstract --

19 Editorial Strategies to improve control of blood pressure in hypertension: moving towards a 70% objective. 2013

Volpe, Massimo / Tocci, Giuliano. · ·Expert Rev Cardiovasc Ther · Pubmed #23750671.

ABSTRACT: -- No abstract --

20 Editorial Shooting beyond score: targeting organ disease to improve risk prediction in hypertension. 2012

Volpe, Massimo / Tocci, Giuliano / Battistoni, Allegra. · ·J Hypertens · Pubmed #22972159.

ABSTRACT: -- No abstract --

21 Editorial The changing role of hypertension societies: shifting gears in Italy. 2012

Volpe, Massimo. · ·High Blood Press Cardiovasc Prev · Pubmed #22670580.

ABSTRACT: -- No abstract --

22 Editorial High blood pressure & cardiovascular prevention is now on MEDLINE. 2011

Volpe, Massimo. · ·High Blood Press Cardiovasc Prev · Pubmed #21806077.

ABSTRACT: -- No abstract --

23 Editorial Rethinking targets of blood pressure and guidelines for hypertension clinical management. 2010

Volpe, Massimo / Tocci, Giuliano. · ·Nephrol Dial Transplant · Pubmed #20702531.

ABSTRACT: -- No abstract --

24 Review Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. 2018

Omboni, Stefano / Volpe, Massimo. ·Clinical Research Unit, Italian Institute of Telemedicine, Varese, Italy. · Scientific Research Department of Cardiology, Science and Technology Park for Biomedicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation. · Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. · IRCCS Neuromed, Pozzilli, Italy. ·Cardiovasc Ther · Pubmed #30358114.

ABSTRACT: Elevated blood pressure (BP) is a major determinant of morbidity and mortality burden related to cardio-metabolic risk. Current guidelines indicate that controlling and lowering BP promotes cardiovascular (CV) risk reduction. Among antihypertensive agents, angiotensin receptor blockers (ARBs) are characterized by an efficacy profile equivalent to other antihypertensive agents and are provided with excellent tolerability and low discontinuation rates during chronic treatments. Moreover, CV outcomes are reduced by ARBs. Olmesartan is a long-lasting ARB which proved to achieve a comparable or more effective action in lowering BP when compared to other ARBs. Olmesartan, in fact, displayed a larger and more sustained antihypertensive effect over the 24 hours, with a buffering effect on short-term BP variability. These are important features which differentiate olmesartan from the other principles of the same class and that may help to control the increased CV risk in the presence of high BP variability. Olmesartan shows similar benefits as other ARBs in terms of all-cause and CV mortality, and a favorable tolerability profile. Combination of olmesartan with long-lasting calcium-channel blockers and thiazide diuretics represents a rational and effective therapy. Thus, ARBs, including olmesartan, represent one of the most effective and safe treatments for patients with arterial hypertension.

25 Review Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. 2018

Tocci, Giuliano / Figliuzzi, Ilaria / Presta, Vivianne / Miceli, Francesca / Citoni, Barbara / Coluccia, Roberta / Musumeci, Maria Beatrice / Ferrucci, Andrea / Volpe, Massimo. ·Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. giuliano.tocci@uniroma1.it. · IRCCS Neuromed, Pozzilli, IS, Italy. giuliano.tocci@uniroma1.it. · Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. · IRCCS Neuromed, Pozzilli, IS, Italy. ·High Blood Press Cardiovasc Prev · Pubmed #30066227.

ABSTRACT: Uncontrolled hypertension is one of the most common determinant for the persistently high burden of cardiovascular (CV) disease, mostly including coronary artery disease (CAD) and hospital admissions due to acute coronary events. Markedly high blood pressure (BP) levels are also frequently observed during the acute phase of coronary syndromes (both ST-segment and non-ST-segment elevation myocardial infarction and unstable angina). In particular, a sustained raise of BP levels above 180/110 mmHg associated with acute cardiac organ damage, i.e. myocardial ischemia, represents a condition of hypertension emergency and requires rapid hospital admission, prompt pharmacological therapies and non-pharmacological interventions, aimed at restoring coronary flow and preserve vital myocardium. Diagnosis of CAD in hypertensive patients may often be complicated by the concomitant presence of electrocardiographic abnormalities, such as ST-segment depression (at rest or during exercise), which may occur even in the absence of coronary atherosclerosis. Thus, proper identification of CAD may result difficult to perform in the setting of clinical practice, mostly in the presence of left ventricular hypertrophy. In this review, we will briefly discuss diagnostic protocols and pharmacological strategies that can be applied in a setting of hypertension emergency with acute cardiac organ damage in the light of the currently available evidence and recommendations from recent guidelines on hypertension management and control.

Next